A step closer to the use of [ 177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer
A step closer to the use of [ 177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 has established itself as a valuable life-prolonging treatment with high response rates in metastatic castration-resistant prostate cancer.1 [177Lu]Lu-PSMA-617 has shown superior radiographic progression-free survival and health-related quality of life compared with other approved...
Alternative Titles
Full title
A step closer to the use of [ 177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3111421104
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3111421104
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(24)00506-0
